Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MORRIS PLAINS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will report financial results for the fourth quarter...
-
Results in Advanced Small-cell Lung Cancer (SCLC) Patients Appear in Advanced Online Publication of the American Association of Cancer Research Journal, Clinical Cancer ResearchResults in Advanced...
-
MORRIS PLAINS, N.J., June 29, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that its stockholders approved an amendment and restatement...
-
MORRIS PLAINS, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that Michael R. Garone, Vice President, Finance and Chief...
-
MORRIS PLAINS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today reported financial results for the third quarter ended March 31, 2017....
-
MORRIS PLAINS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that it will report financial results for the third quarter...
-
WASHINGTON, April 05, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today reported that sacituzumab govitecan (IMMU-132), the Company’s lead...
-
WASHINGTON, April 04, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today reported that labetuzumab govitecan (IMMU-130), the Company’s second...
-
Preclinical Study Presented at 2017 AACR Annual Meeting Pharmacokinetics of Sacituzumab Govitecan in Patients with Diverse Solid Tumors also Presented WASHINGTON, April 04, 2017 (GLOBE NEWSWIRE)...
-
MORRIS PLAINS, N.J., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that the Company will present at Cowen and...